Genetics, Genomics & Molecular Diagnostics News

The University of California-led party can still appeal the decision from the US Patent and Trademark Office, but it has been dealt a major setback.

Elizabeth Mansfield, who spearheaded regulations at the agency for precision medicine and next-generation sequencing, will lead regulatory affairs at Illumina-backed Grail.

The Broad Institute's lawyers used statements from Jennifer Doudna to undermine UC's case that one could expect CRISPR/Cas9 to work in eukaryotic cells.

Several MDx firms recently touted BCBS's Evidence Street opinions on their tests as milestones, and Palmetto GBA's MolDx may soon be using its assessments.

In a recent study, project researchers highlighted the need to use findings from outside proteomics as they chase down the remaining unidentified proteins.

The company had been warned by Nasdaq in August that it failed to comply with a minimum $10 million stockholder equity requirement to remain listed on the exchange. 

NanoString said its sequencing technology harnesses its expertise in optical barcodes and that it would develop it for clinical use to complement its existing products.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.

Genotoxicity workflows performed manually are subject to workflow bottlenecks, where the throughput is inherently limited, and active time spent performing the tests reduces the lab’s overall efficiency. Additionally, variability associated with operator technique and laboratory conditions could lead to a loss in precision, or worse, systematic errors that can skew results. This article demonstrates automated imaging as it pertains to the comet and gamma-H2AX assays in order to simplify genotoxicity assay workflows and provide robust results.

Stringent guidelines of quality assurance and control (QA/QC) serve as the foundation for dependable and reproducible results in any analytical endeavor. Here we highlight step-by-step, the measures implemented by Myriad RBM that take Luminex xMAP technology to a high level of reproducibility and ruggedness. The Myriad RBM platform combines the sensitivity and dynamic range of microsphere-based immuno-multiplexing with the precision and dependability of automated liquid handling.

Serpins (serine protease inhibitors) regulate key intracellular and extracellular pathways, but conformational variants of this complex family of protease inhibitors are often underrepresented in proteomic analyses. This white paper from Biotech Support Group describes bead-based separation products within the NuGel family of proteomic enrichment products that enable investigations of serum serpins. Functional profiles of serpin proteoforms can then be associated with disease phenotypes, gene mutations, and dysregulated mechanisms.